Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Tang, Yong ^a   Liu, Fenghua ^a   Zheng, Chunning ^b   Sun, Shaochuan ^b   Jiang, Yingsheng ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Chemoresistance; Clusterin; ERK1 2; Gemcitabine; Gene treatment; Pancreatic cancer

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CUSTIRSEN; GEMCITABINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL LINE; CELL PROLIFERATION; CHEMOSENSITIVITY; CLUSTERIN GENE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MOUSE; NICK END LABELING; NONHUMAN; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTERIN; DEOXYCYTIDINE; FLAVONOIDS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 3; PANCREATIC NEOPLASMS; THIONUCLEOTIDES;

EID: 84865996014     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-73     Document Type: Article

References (51)

1. Cancer statistics,2006. Jemal A, Siegel R, Ward E, CA Cancer J Clin 2006 56 106 130 10.3322/canjclin.56.2.106 16514137
2. Cytotoxic therapy for advanced pancreatic adenocarcinoma. OReilly EM, Abou-Alfa GK, Semin Oncol 2007 34 347 353 10.1053/j.seminoncol.2007.05.009 17674963 (Pubitemid 47176624)
3. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Moore MJ, Goldstein D, Hamm J, J Clin Oncol 2007 25 1960 1966 10.1200/JCO.2006.07.9525 17452677 (Pubitemid 46972777)
4. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. Gleave M, Chi KN, Ann N Y Acad Sci 2005 1058 1 15 10.1196/annals.1359.001 16394121
5. Clusterin. Jones SE, Jomary C, Int J Biochem Cell Biol 2002 34 427 431 10.1016/S1357-2725(01)00155-8 11906815 (Pubitemid 34242756)
6. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Springate CM, Jackson JK, Gleave ME, Burt HM, Cancer Chemother Pharmacol. 2005 56 239 247 10.1007/s00280-004- 0997-5 15864591 (Pubitemid 40941793)
7. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME, Neoplasia 2001 3 360 367 10.1038/sj.neo.7900174 11571636 (Pubitemid 32801886)
8. The role of clusterin (CLU) in malignant transformation and drug resistance in breast carcinomas. Redondo M, Tellez T, Roldan MJ, Adv Cancer Res 2009 105 21 43 19879421
9. Clusterin (CLU) and lung cancer. Panico F, Rizzi F, Fabbri LM, Bettuzzi S, Luppi F, Adv Cancer Res 2009 105 63 76 19879423
10. Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays. Bi J, Guo AL, Lai YR, Li B, Zhong JM, Wu HQ, Xie Z, He YL, Lv ZL, Lau SH, Wang Q, Huang XH, Zhang LJ, Wen JM, Guan XY, Neoplasma 2010 57 191 198 10.4149/neo-2010-03-191 20353268
11. Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Hazzaa SM, Elashry OM, Afifi IK, Pathol Oncol Res 2010 16 101 109 10.1007/s12253-009-9196-3 19757199
12. Clusterin as a potential marker in distinguishing cervical neoplasia. Lokamani I, Looi ML, Ali SA, Dali AZ, Jamal R, Anal Quant Cytol Histol 2011 33 223 228 21980627
13. Overexpression of clusterin in human breast carcinoma. Redondo M, Villar E, Torres-Mũoz J, Tellez T, Morell M, Petito CK, Am J Pathol 2000 157 393 399 10.1016/S0002-9440(10)64552-X 10934144 (Pubitemid 30626904)
14. Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Xie D, Lau SH, Sham JS, Wu QL, Fang Y, Liang LZ, Che LH, Zeng YX, Guan XY, Cancer 2005 103 277 283 10.1002/cncr.20765 15578711 (Pubitemid 40129286)
15. Overexpression of clusterin in human hepatocellular carcinoma. Kang YK, Hong SW, Lee H, Kim WH, Hum Pathol 2004 35 1340 1346 10.1016/j.humpath.2004.07. 021 15668890 (Pubitemid 39601573)
16. Oncogenic role of clusterin overexpression in multistage colorectal tumorigenesis and progression. Xie D, Sham JS, Zeng WF, Che LH, Zhang M, Wu HX, Lin HL, Wen JM, Lau SH, Hu L, Guan XY, World J Gastroenterol 2005 11 3285 3289 15929184 (Pubitemid 40973902)
17. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. Kurahashi T, Muramaki M, Yamanaka K, Hara I, Miyake H, BJU Int 2005 96 895 899 10.1111/j.1464-410X.2005.05733.x 16153225 (Pubitemid 41391404)
18. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, Kozlowski JM, Sensibar JA, Clin Cancer Res 1997 3 1707 1711 9815554 (Pubitemid 27444708)
19. Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment. Bijian K, Mlynarek AM, Balys RL, Jie S, Xu Y, Hier MP, Black MJ, Di Falco MR, LaBoissiere S, Alaoui-Jamali MA, J Proteome Res. 2009 8 2173 2185 10.1021/pr800979e 19284786
20. Clusterin immunoexpression and its clinical significance in patients with non-small cell lung cancer. Li H, Liu S, Zhu X, Yang S, Xiang J, Chen H, Lung 2010 188 423 431 10.1007/s00408-010-9248-1 20614220
21. Clusterin expression in primary and metastatic melanoma. Busam KJ, Kucukgol D, Eastlake-Wade S, Frosina D, Delgado R, Jungbluth AA, J Cutan Pathol 2006 33 619 623 10.1111/j.1600-0560.2006.00481.x 16965336 (Pubitemid 44370059)
22. Clusterin expression in malignant lymphomas: a survey of 266 cases. Saffer H, Wahed A, Rassidakis GZ, Medeiros LJ, Mod Pathol 2002 15 1221 1226 10.1097/01.MP.0000036386.87517.AA 12429802 (Pubitemid 35435141)
23. Induction of clusterin by AKT-role in cytoprotection against docetaxel in prostate tumor cells. Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S, Djeu JY, Mol Cancer Ther 2010 9 1831 1841 10.1158/1535-7163.MCT-09-0880 20501799
24. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Trougakos IP, Lourda M, Antonelou MH, Clin Cancer Res 2009 15 48 59 10.1158/1078-0432.CCR-08-1805 19118032
25. Clusterin inhibits apoptosis by interacting with activated Bax. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY, Nat Cell Biol 2005 7 909 915 10.1038/ncb1291 16113678 (Pubitemid 41486292)
26. Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. Ammar H, Closset JL, J Biol Chem 2008 283 12851 12861 10.1074/jbc.M800403200 18321852
27. Clusterin, a novel modulator of TGF-beta signaling, is involved in Smad2/3 stability. Lee KB, Jeon JH, Choi I, Kwon OY, Yu K, You KH, Biochem Biophys Res Commun 2008 366 905 909 10.1016/j.bbrc.2007.12.033 18082619
28. Clusterin facilitates COMMD1 and I-kB degradation to enhance NF-kB activity in prostate cancer cells. Zoubeidi A, Ettinger S, Beraldi E, Mol Cancer Res In press 2009
29. Clusterin confers gemcitabine resistance in pancreatic cancer. Chen Q, Wang Z, Zhang K, Liu X, Cao W, Zhang L, Zhang S, Yan B, Wang Y, Xia C, World J Surg Oncol. 2011 24 9 59
30. ERK1/2 MAP kinases in cell survival and apoptosis. Lu Z, Xu S, IUBMB Life. 2006 58 621 31 10.1080/15216540600957438 17085381 (Pubitemid 44691463)
31. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N, J Cell Biochem 2000 79 355 369 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0 10972974
32. Clusterin enhances proliferation of primary astrocytes through extracellular signal-regulated kinase activation. Shin YJ, Kang SW, Jeong SY, Shim YJ, Kim YH, Kim BM, Kee SH, Park JJ, Park IS, Min BH, NeuroReport 2006 17 1871 5 10.1097/WNR.0b013e328010ac99 17179861 (Pubitemid 46006289)
33. Clusterin induces matrix metalloproteinase-9 expression via ERK1/2 and PI3K/Akt/NF-B pathways in monocytes/macrophages. Shim YJ, Kang BH, Jeon HS, Park IS, Lee KU, Lee IK, Park GH, Lee KM, Schedin P, Min BH, J Leukoc Biol 2011 90 761 9 10.1189/jlb.0311110 21742938
34. Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Chou TY, Chen WC, Lee AC, Hung SM, Shih NY, Chen MY, Cell Signal 2009 21 704 11 10.1016/j.cellsig.2009.01.008 19166932
35. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Miyake H, Hara I, Gleave ME, Int J Urol 2005 12 785 94 10.1111/j.1442-2042.2005.01173.x 16201973 (Pubitemid 41726972)
36. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. Sowery RD, Hadaschik BA, So AI, BJU Int 2008 102 389 97 10.1111/j.1464-410X. 2008.07618.x 18336596 (Pubitemid 352019195)
37. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. Gleave M, Miyake H, World J Urol 2005 23 38 46 10.1007/s00345-004-0474-0 15770517 (Pubitemid 40430679)
38. Nuclear Factor-KB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells. Xue P, Thiruvengadam A, Tameyoshi Y, Levin PA, Vijaya R, Baoan J, Gabriel L-B, Vivas-Mejia PE, Sood AK, McConkey DJ, Logsdon CD, Clin Cancer Res 2008 14 8143 8151 10.1158/1078-0432.CCR-08-1539 19088029
39. Adjuvant treatment of pancreatic cancer. Neoptolemos JP, Eur J Cancer 2011 47 Suppl 3 378 80 21944022
40. Current status of adjuvant therapy for pancreatic cancer. Katz MH, Fleming JB, Lee JE, Pisters PW, Oncologist 2010 15 1205 1213 10.1634/theoncologist.2010-0121 21045189
41. Chemotherapy in pancreatic adenocarcinoma. Squadroni M, Fazio N, Eur Rev Med Pharmacol Sci 2010 14 386 394 20496553
42. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE, Clin Cancer Res 2004 10 2307 2318 10.1158/1078-0432.CCR-1183-3 15073106 (Pubitemid 38445688)
43. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P, Urology 2001 58 39 49 10.1016/S0090-4295(01)01241-9 11502446 (Pubitemid 32743407)
44. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Miyake H, Hara I, Kamidono S, Gleave ME, Clin Cancer Res 2001 7 4245 4252 11751526 (Pubitemid 34044651)
45. Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer. Xue HY, Wong HL, Eur J Pharm Biopharm 2012 81 1 24 32 10.1016/j.ejpb.2012.02.005 22369881
46. Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Hassan MK, Watari H, Christenson L, Bettuzzi S, Sakuragi N, Tumour Biol 2011 32 1031 47 10.1007/s13277-011-0207-0 21761117
47. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Johnson GL, Lapadat R, Science 2002 298 1911 1912 10.1126/science.1072682 12471242 (Pubitemid 35425238)
48. Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line. Guan J, Chen XP, Zhu H, Luo SF, Cao B, Ding L, World J Gastroenterol 2004 10 3522 3527 15526378 (Pubitemid 39549558)
49. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, DAssoro AB, Adv Enzyme Regul. 2006 46 249 279 10.1016/j.advenzreg.2006.01.004 16854453 (Pubitemid 44301348)
50. Doxycycline enhances the Ras-MAPK signaling and proliferation of mouse thymic epithelial cells. Chen X, Xia S, Li R, Liu H, Huang Y, Qian X, Xiao X, Xu X, Lin X, Tian Y, J Cell Biochem 2009 107 494 503 10.1002/jcb.22147 19330805
51. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Arti S, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, Michele C, Testa JR, Mossman BT, Mol Cancer 2010 9 314 10.1186/1476-4598-9- 314 21159167